Power Law company profile

Rec-Biotechnology

Biotech & Life Sciences · Taizhou, China · Founded 2012 Unicorn

Dedicated to the R&D, production and commercialization of innovative vaccines, leveraging its core technology platforms

Valuation

$100–500M

Latest valuation · May/2026

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

14 investors on Rec-Biotechnology's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 2 investors entered at this stage

Oriental Fortune Capital

CR Capital Management

Series B+ 12 investors entered at this stage

HT Capital

China Everbright Limited

Temasek

Legend Capital

LYFE Capital

Sequoia

Boyu Capital

Lake Bleu Capital

YuanBio Venture Capital

Qingsong Capital

Shenzhen Cornerstone Asset Management

Vertex Holdings

Global footprint

Where Rec-Biotechnology has talent and traffic

Workforce by country

1 countries with
team presence

🇨🇳 China100%

1 country shown

Web traffic by country

1.7K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Market sentiment

What the market is saying about Rec-Biotechnology

An AI-synthesized read of the highest-engagement posts about Rec-Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Rec-Biotechnology on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles